Business Wire

SOFTSERVE

19.10.2021 13:07:55 CEST | Business Wire | Press release

Share
SoftServe Appoints Alfredo Rubina as VP Financial Services Domain Solutions and Consulting

SoftServe , a leading digital authority and consulting company, has appointed Alfredo Rubina as Vice President Financial Services Domain Solutions and Consulting, effective immediately. Rubina has 25 years of international experience in enterprise technology and software sales, business development, and general management in the financial services industry. As VP Financial Services, he will be responsible for defining and building SoftServe’s financial services domain growth and go-to-market strategy in EMEA, including driving vertical roadmap and the development of offerings/accelerators, building sales channels, and developing relationships with client organizations and partner companies. Rubina will report to Volodymyr Semenyshyn, SoftServe’s Executive Vice President EMEA and Financial Services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211019005014/en/

"Alfredo brings to SoftServe impressive experience working internationally with top-tier financial and corporate firms at the highest levels," said Semenyshyn. "I am excited to have him oversee our financial services domain and build and lead teams that deliver solutions and services that help our clients reach their goals."

“SoftServe has a history of successfully delivering client value through developing win-win relationships and finding innovative solutions in a fast-changing business environment,” said Rubina. “As VP Financial Services, I will focus on helping financial institutions identify trends, master challenges, unlock opportunities and enable transformation through new digital technologies. It is my goal to help customers grow their business, increase efficiency and reduce costs, as well as to fuel SoftServe’s continuous and rapid rate of growth in EMEA.”

Prior to joining SoftServe, Rubina managed strategy and go-to-market as Head of IHS Markit’s Digital franchise in EMEA and Latin America, with full P&L responsibility for the business and its successful growth with new clients, customer segments, and markets in different countries.

Before IHS Markit, Rubina was with Interactive Data Managed Solutions AG for more than 15 years, establishing and expanding the digital business into a leading global provider of bespoke solutions for the financial industry.

Rubina was also previously with investment banking sector and the German retail banking and savings bank organizations, holding a variety of account management, sales, and business development roles.

Rubina studied Business Informatics and Business Administration at the University of Mannheim after a Banking Professional apprenticeship at Sparkasse Mannheim.

A cosmopolitan German of Peruvian origin, Rubina loves sports and is an avid fan of music. Together with his wife, he raises two daughters and cares for a very special and rare Bergamasco Shepherd. A vehement supporter of social responsibility, environmental protection, and animal welfare, Rubina is an active volunteer at The Tafel, the largest food donation organization in Germany, and is engaged with The German Animal Welfare Federation. He also compensates his CO2 footprint with Compensators, a non-profit organization that buys emission allowances from the European Emissions Trading Scheme and decommissions them permanently.

About SoftServe

SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.

SoftServe delivers open innovation, from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.

Visit our website , blog , LinkedIn , Facebook , and Twitter pages.

Link:

ClickThru

Social Media:

https://www.facebook.com/SoftServeInc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release

Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa

ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release

ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document

SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release

Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as

Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release

Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release

-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye